Mullen John T, Rodriguez-Bigas Miguel A, Chang George J, Barcenas Carlos H, Crane Christopher H, Skibber John M, Feig Barry W
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-1402, USA.
Ann Surg Oncol. 2007 Feb;14(2):478-83. doi: 10.1245/s10434-006-9221-7. Epub 2006 Nov 14.
The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy. For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice. The purpose of this study is to review our experience with salvage surgery in this group of patients.
From 1990-2002, 31 patients underwent radical salvage surgery with curative intent after failure of initial sphincter-conserving therapy, and the medical records of these patients were retrospectively reviewed. Clinicopathologic variables were determined and comparisons performed with the Cox proportional hazards model. Survival was calculated by the Kaplan-Meier method.
Eleven patients underwent radical salvage surgery for persistent disease and 20 patients for recurrent disease. The median follow-up time was 29 months. The actuarial 5-year overall survival was 64%. Twelve patients developed recurrent disease after radical salvage surgery. Patients who received an initial radiation dose of less than 55 Gy had a significantly worse survival than those who received at least 55 Gy as part of their initial treatment (5-year overall survival 37.5% vs. 75%; age-adjusted hazard ratio 8.2 [95% CI: 1.1-59.8], P = .037). The presence of positive lymph nodes at presentation also adversely affected survival (P < .05). Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients. However, patients who initially present with node-positive disease and patients who receive a radiation dose of less than 55 Gy as part of their initial chemoradiation therapy regimen have a worse prognosis after radical salvage surgery.
肛管表皮样癌的标准治疗包括放疗和化疗联合应用。对于出现持续性或局部复发性疾病的患者,挽救性腹会阴联合切除术是首选治疗方法。本研究的目的是回顾我们在这组患者中进行挽救性手术的经验。
1990年至2002年,31例患者在初始保留括约肌治疗失败后接受了根治性挽救性手术,对这些患者的病历进行回顾性分析。确定临床病理变量,并使用Cox比例风险模型进行比较。采用Kaplan-Meier法计算生存率。
11例患者因持续性疾病接受根治性挽救性手术,20例患者因复发性疾病接受手术。中位随访时间为29个月。5年总生存率为64%。12例患者在根治性挽救性手术后出现疾病复发。初始放疗剂量低于55 Gy的患者生存率明显低于初始治疗时接受至少55 Gy放疗的患者(5年总生存率37.5%对75%;年龄校正风险比8.2[95%CI:1.1-59.8],P=0.037)。就诊时存在阳性淋巴结也对生存率有不利影响(P<0.05)。未发现对生存率有影响的因素包括持续性疾病与复发性疾病的存在、肿瘤(T)分期和切除切缘情况。
大多数肛管表皮样癌持续性或局部复发性疾病患者在挽救性手术后可实现长期生存。然而,就诊时初始存在淋巴结阳性疾病的患者以及初始放化疗方案中放疗剂量低于55 Gy的患者,在根治性挽救性手术后预后较差。